drugset / Trial / NCT02576444
OLAParib COmbinations
Phase 2
Terminated
67 enrolled
Joseph Paul Eder
Dana-Farber Cancer Institute · collabThe Cleveland Clinic · collabVanderbilt-Ingram Cancer Center · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of this phase II trial is to determine tumor overall response rate (ORR) in molecularly selected patients with measurable disease as assessed by the Response Evaluation Criteria in Solid Tumors (RECIST), before versus after 16 weeks of treatment across tumor types in each arm of the study.
Timeline
- Start
- 2015-11
- Primary completion
- 2019-11-18
- Completion
- 2019-11-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adavosertib | Small molecule | — | — |
| Subject | Capivasertib | Small molecule | 640 mg | — |
| Subject | Ceralasertib | Small molecule | 160 mg | — |
| Subject | Olaparib | Small molecule | 300 mg | Oral |